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Background: C-reactive protein is a well established marker of inflammation and has been used to predict future
cardiovascular disease. It is still controversial if it plays an active role in the development of cardiovascular disease.
Recently, polymorphisms in the gene for HNF1a have been linked to the levels of C-reactive protein and coronary
artery disease.
Methods: We investigated the association of the rs2259816 polymorphism in the HNF1A gene with the circulating
level of C-reactive protein and the hazard of coronary artery disease in the LURIC Study cohort.
Results: Compared to CC homozygotes, the level of C-reactive protein was decreased in carriers of at least one
A-allele. Each A-allele decreased CRP by approximately 15%. The odds ratio for coronary artery disease was only
very slightly increased in carriers of the A-allele and this association did not reach statistical significance.
Conclusions: In the LURIC Study cohort the A-allele of rs2259816 is associated with decreased CRP but not with
coronary artery disease.
Background
C-reactive protein (CRP) is a well established biochem-
ical marker of inflammation and has been used to pre-
dict future cardiovascular disease [1-3]. As its level is
increased in patients suffering from coronary artery dis-
ease (CAD) the idea has been put forward that it might
play an active role in the development of the disease.
Although numerous studies have been conducted, this
issue has not been finally settled yet [4-6]. Most of these
studies didn’t find an association between CRP and
CAD [7-13] whereas a few did present some evidence in
favor of this idea [14-16].
A recent meta-analysis has shown that associations of
CRP with ischemic vascular disease depend considerably
on conventional risk factors and other markers of
inflammation making a causal role of CRP in the devel-
opment of CAD also unlikely [17].
Genetic factors have been estimated to have a great
influence on the variance in plasma CRP level [18-20].
A number of polymorphisms of the CRP gene (MIM
123260) or its promoter that act in this way have been
described so far [8-11,14-16,21-32] but they only
account for a minor part of the assumed heritability.
Recently, polymorphisms in the HNF1A gene (also
known asTCF1, MIM 142410) have been linked to the
levels of C-reactive protein and coronary artery disease
[33-36]. This gene encodes the transcription factor
hepatocyte nuclear factor (HNF)-1a which regulates the
transcription of numerous genes in miscellaneous tis-
sues, including genes that are expressed exclusively in
the liver [37-40]. The CRP gene promoter contains a
HNF-1a binding site which is involved in the regulation
of basal and constitutive CRP synthesis in the liver [41].
In our study we attempted to confirm the reported
association of rs2259816 to CRP and CAD in the
LURIC Study cohort.
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Study design and participants
The Ludwigshafen Risk and Cardiovascular Health
(LURIC) study includes consecutive white patients hos-
pitalized for coronary angiography between June 1997
and May 2001. A detailed description of LURIC has
been published [42]. The study was approved by the
ethics review committee at the “Landesärztekammer
Rheinland-Pfalz” (Mainz, Germany). Written informed
consent was obtained from each of the participants.
Clinical indications for angiography were chest pain or
non-invasive tests consistent with myocardial ischemia.
To limit clinical heterogeneity, individuals suffering
from acute illness other than acute coronary syndromes,
chronic non-cardiac diseases and a history of malig-
nancy within the five past years were excluded.
CAD has been defined angiographically using the maxi-
mum luminal narrowing estimated by visual analysis.
CAD was defined as the presence of a visible luminal nar-
rowing (> 20% stenosis) in at least one of 15 coronary
segments according to a classification of the American
Heart Association [43]. Individuals with stenosis < 20%
were considered as not having CAD. To examine the
impact of other definitions of CAD on the current analy-
sis, we provisionally used the presence of one stenosis
> 50% (n = 2158) as a criterion. MI was defined as evi-
dence for any MI (acute, previous, ST elevation MI,
STEMI, or non ST elevation MI, NSTEMI). Acute MI
was defined as a MI that had occurred within the four
weeks prior to enrolment into LURIC. A previous MI
was diagnosed if a MI had been survived for more than
one month before enrolment into LURIC. A definite
STEMI was diagnosed if typical ECG changes were pre-
sent along with prolonged chest pain refractory to sublin-
gual nitrates and/or enzyme or troponin T elevations.
NSTEMI was diagnosed if symptoms and/or enzyme cri-
teria, but not the ECG criteria for STEMI were met. Pre-
vious MI was also graded as definite if a hospitalisation
with a discharge diagnosis of MI was documented.
Among the 3113 individuals in whom rs2259816 gen-
otypes were available, 665 (21.4%) had no angiographic
CAD while 2448 (78.6%) had CAD.
Diabetes mellitus was diagnosed according to the cri-
teria of the American Diabetes Association [44]. Further,
individuals with a history of diabetes or treatment with
oral antidiabetics or insulin were considered diabetic.
Hypertension was defined as a systolic and/or diastolic
blood pressure ≥ 140 and/or ≥ 90 mm Hg or a signifi-
cant history of hypertension.
Laboratory Procedures
Fasting blood samples were obtained by venipuncture in
the early morning. ‘Sensitive’ C-reactive protein was
measured by immunonephelometry on a Behring
Nephelometer II (N High Sensitivity CRP, Dade Behring,
Marburg, Germany) after completion of the patient
recruitment in 2001 in samples stored at -80°C. In the
C-reactive protein assay used, the limit of detection
for C-reactive protein is 0.17 mg/L; it is linear up to
500 mg/L. The lowest and the highest C-reactive protein
concentrations encountered in this study were 0.17 and
269 mg/L, respectively. Blood glucose was determined
enzymatically using the hexokinase/glucose-6-phosphate
dehydrogenase method (Roche Diagnostics, Mannheim,
Germany). Lipoproteins were separated by a combined
ultracentrifugation-precipitation method (b-quantifica-
tion) [42]. Cholesterol and triglycerides were measured
with enzymatic reagents from WAKO (Neuss, Germany)
on a WAKO R30 or Olympus AU640 analyser [42].
Analysis of the rs2259816 genotype
Genomic DNA was prepared from EDTA anticoagulated
peripheral blood by using a common salting-out proce-
dure. The C/A polymorphism rs2259816 was genotyped
b ya5 ’ exonuclease assay (Taqman®). Primer and probe
sets were designed and manufactured using Applied Bio-
system’s ‘Assay-by-Design’ custom service.
Statistics
Continuous variables were first tested for normality and
then compared between groups by univariate analysis of
variance (ANOVA). CRP was not normally distributed
and had to be logarithmically transformed before per-
forming ANOVA. Co-variables were used as indicated.
In models assuming a co-dominant (additive) effect of
the alleles, genotypes were coded as 0, 1, and 2, respec-
tively, and genotypes were either treated as interval-scaled
or categorical variables, the most frequent genotype being
considered as the reference category in the latter case.
When assuming a dominant effect, the genotype CC was
coded as 0, and the combined remaining ones were
coded as 1. When assuming a recessive effect, the geno-
types CC and AC were coded as 0, genotype AA as 1.
Further, the estimated marginal means of the dependent
variables along with their 95% confident intervals (CI) are
reported in the ANOVA procedures and the least signifi-
cant difference t-test was used for post hoc comparisons.
Estimated marginal means are not observed means;
rather they represent predicted means estimated at the
co-variables held at their respective actual means. Finally,
we analyzed the association between rs2259816 genotypes
and angiographic CAD in an analogous fashion by logis-
tic regression. Multivariable adjustment was carried out
in two steps, first for sex and age, and then, in addition,
for cardiovascular risk factors (body mass index, diabetes
mellitus, hypertension, smoking, LDL-C, HDL-C and TG.
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ered statistically significant. The SPSS 16.0 statistical
package (SPSS Inc., Chicago, IL, USA) was used.
Results
Study participants
We included 3113 subjects in the current analysis. Com-
pared to the control group without CAD, patients with
angiographic CAD were significantly older; current or
past smoking, diabetes mellitus, and hypertension were
more prevalent. CAD patients had higher systolic blood
pressure, higher fasting glucose, higher triglycerides and
lower HDL-C. Crude LDL-C concentrations were higher
in controls, due to the fact that 57.1% of CAD patients
were treated with lipid-lowering drugs compared to
18.3% of controls. When we accounted for the use of
lipid-lowering drugs, age, and gender, however, LDL-C
was significantly higher in CAD patients (adjusted mean
118 mg/dl) than in controls (adjusted mean 113 mg/dl).
Body mass index and diastolic blood pressure were simi-
lar between patients and controls (Table 1).
Association of rs2259816 with CRP
To analyze the association of levels of CRP with
rs2259816 genotype, we used analysis of variance in
which the genotype groups (defined by the presence or
the absence of an A-allele) were included as main
effects; statistical adjustments were made for age, sex
and cardiovascular risk factors, namely body mass index,
diabetes mellitus, hypertension, smoking, LDL-C, HDL-
C and TG (Figure 1).
Compared to CC homozygotes, carriers of the A-allele
had significantly lower plasma concentration of CRP
(P < 0.001). The circulating plasma concentration
decreased from 3.88 mg/l (3.63 - 4.16) in CC homozy-
gotes to 3.43 mg/l (3.21 - 3.65) in heterozygotes and to
2.95 mg/l (2.64 - 3.31) in AA homozygotes. As statins
also lower CRP we repeated our analysis including only
patients not receiving lipid lowering therapy but this
yielded basically the same results (data not shown).
rs2259816 and coronary artery disease
Compared to CC homozygotes, the prevalence of CAD
was basically the same in CA heterozygotes with OR
ranging from 1.005 to 1.038, depending on the statistical
model (Table 2). Even for AA homozygotes there was
only a slightly higher increase with OR ranging from
1.050 to 1.083. Both associations were not statistically
significant. There was no significant association between
rs2259816 and CAD in any of the tested models either.
We further looked for an association of rs2259816 with
the friesinger score, a quantitative measure of the severity
of CAD. ANOVA analysis didn’t show a significant differ-
ence between the three genotype groups (Figure 2).
Discussion
Recently, the discovery that the reduction of CRP levels
in individuals who are not considered to be at high risk
for cardiovascular disease by National Cholesterol Edu-
cation Program guidelines significantly decreased the
rate of first major cardiovascular events as well as total
mortality has renewed the interest in CRP as possible
biomarker for deciding whether an individual should
receive treatment [45,46]. The JUPITER trial showed the
benefit of statin treatment even for individuals with high
CRP but normal LDL-C [45,47].
Table 1 Baseline characteristics and risk factors in patients with angiographically proven CAD as compared to controls
without CAD
No CAD CAD P
1
(n = 665) (n = 2448)
Age (years) means ± SD 58 ± 12 64 ± 10 < 0.001
Body mass index (kg/m
2) means ± SD 27 ± 4 28 ± 4 n.s.
Smoker (former and current) 324 (49%) 1675 (68%)
Diabetes mellitus 125 (19%) 872 (36%)
Systemic Hypertension 417 (63%) 1841 (75%)
Systolic blood pressure (mm Hg) means ± SD 136 ± 22 142 ± 24 0.014
3
Diastolic blood pressure (mm Hg) means ± SD 80 ± 11 81 ± 11 n.s.
Fasting blood glucose (mg/dl) means ± SD 105 ± 28 116 ± 37 < 0.001
LDL-C(mg/dl) means ± SD 120 ± 31 116 ± 35 0.001
4









1Analysis of variance or logistic regression, respectively, adjusted for age and gender.
2Analysis of variance adjusted for gender only.
3Analysis of variance additionally adjusted for use of lipid-lowering drugs, beta blockers, ACE inhibitors, AT1 receptor antagonists, calcium channel blockers and
diuretics.
4Analysis of variance additionally adjusted for use of lipid-lowering drugs.
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is due to genetic causes attempts have been made to
identify the responsible genes.
Besides polymorphisms in the CRP gene itself other
genes have been identified, one of them being the gene
for transcription factor hepatocyte nuclear factor (HNF)-
1a. Several polymorphisms in this gene have been linked
to lower CRP [33,34]. We analyzed one of these poly-
morphisms, rs2259816, in the LURIC cohort. In LURIC
CRP is increased in CAD patients compared to healthy
controls but the increase is only significant for patients
with acute coronary syndromes, not for patients with
stable CAD [48]. For the rs2259816 polymorphism we
found a highly significant association with circulating
levels of CRP confirming other reports. Individuals
homozygous for the rare A allele showed an approxi-
mately 25% lower CRP compared to individuals homozy-
gous for the C allele. However, this SNP had no impact
o nt h er i s ko fC A Di nL U R I C .T h eo d d sr a t i oe v e n
increased marginally for heterozygous or homozygous
carriers of the A allele compared to CC homozygotes but
this increase did not reach statistical significance. On the
other hand our study has only a limited power to detect
small effects on the risk of CAD. The estimated marginal
mean of CRP in CC homozygotes was 3.88 mg/L com-
pared to 2.95 mg/L in AA homozygotes. According to
Figure 1 Levels of CRP according to rs2259816 genotype. CRP by rs2259816 genotype. Displayed are the estimated marginal means (± 95%
confidence intervals) of a linear model (ANOVA) adjusted for age, gender, smoking (never, former, current), body mass index, diabetes mellitus,
hypertension, LDL-C, HDL-C and TG. The A-allele of rs2259816 was associated with significantly lower CRP (P< 0.001)
Table 2 Odds ratios (OR) for angiographic CAD according to the rs2259816 genotype
rs2259816 genotype Model 1 OR (95% CI) P Model 2 OR (95% CI) P Model 3 OR (95% CI) P





1 (n = 1395) 1.005 (0.835 - 1.210) 0.957 1.013 (0.832 - 1.232) 0.900 1.038 (0.847 - 1.272) 0.717
AA
1 (n = 454) 1.050 (0.807 - 1.367) 0.716 1.045 (0.792 - 1.380) 0.755 1.083 (0.811 - 1.445) 0.590
CC vs CA vs AA 1.020 (0.901 - 1.154) 0.755 1.020 (0.895 - 1.162) 0.766 1.040 (0.908 - 1.191) 0.572
CC vs CA + AA 1.016 (0.835 - 1.209) 0.860 1.021 (0.848 - 1.227) 0.829 1.049 (0.866 - 1.270) 0.626
CC + CA vs AA 1.047 (0.820 - 1.338) 0.712 1.038 (0.802 - 1.344) 0.775 1.061 (0.812 - 1.387) 0.664
1Genotypes treated as categorical variables and compared to the reference category.
Model 1: unadjusted.
Model 2: adjusted for age, and gender.
Model 3: in addition adjusted for type 2 diabetes, body mass index, smoking, hypertension, LDL-C, HDL-C, TG
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between CRP and CAD, this difference should translate
into an OR for CAD of only 1.13. To increase our power
we looked for an association of rs2259816 with the frie-
singer index which is a quantitative score of the severity
of CAD. Although there is also a slight increase in frie-
singer score for carriers of the A allele this difference was
not significant, strengthening the notion that there is no
causal relationship between CRP and CAD.
These findings are in line with Grammer et al. who
didn’t find an association of polymorphisms in the CRP
gene itself and CAD in LURIC [12] and support the
view that CRP does not play a causal role in the devel-
opment of CAD.
Nevertheless, we think that HNF-1a might play an
important role as a link between metabolic and inflam-
matory pathways. As such it could be involved in the
pathogenesis of atherosclerosis and further work is
required to define the role of HNF-1a more exactly.
Conclusions
In the LURIC Study cohort the A-allele of the
rs2259816 polymorphism in the HNF1A gene is asso-
ciated with decreased CRP but not with coronary artery
disease. These results support the view that CRP does
not play an active role in the development of CAD.
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